Can the predictive value of multiparametric MRI for prostate cancer be improved by a liquid biopsy with SelectMDx?
Mohammad Sajjad RahnamaiChristian BachMaximilian Schulze-HagenChristiane K KuhlThomas Alexander VögeliPublished in: Cancer reports (Hoboken, N.J.) (2021)
In this real-life selected group of consecutive patients with a confirmed positive PCa biopsy and available mpMRI, the liquid biopsy test with SelectMDx, did not provide an additional information about the PCa clinical significance. The addition of SelectMDx was only found valuable in those patients who had a very high-risk PCa (ie, GS ≥8) who had a positive SelectMDx test outcome despite of a negative mpMRI outcome.